Y-MABS THERAPEUTICS
YmAbs is a clinical stage biopharmaceutical company that discovers and develops innovative treatments for cancer patients through immunotherapies. YmAbs utilizes its platform technologies to create next-generation humanized, affinity matured bispecific antibodies. To further improve its bispecific antibodies, the company collaborates on the development of a novel human protein tag that dimerizes T-cell engaging bispecific antibodies, which enables higher tumor binding and results in a longer ser... um half-life and a significantly greater T-cell mediated killing of tumor cells. YmAbs' treatments claims to potentially reduce longer-term toxicities associated with current chemotherapeutics and provide the potential for curative therapy even for patients with widespread disease. YmAbs’ goal is to drive multiple product candidates in select solid tumor cancers to FDA approval.
Y-MABS THERAPEUTICS
Social Links:
Industry:
Biotechnology Health Care Medical Therapeutics
Founded:
2015-04-01
Address:
New York, New York, United States
Country:
United States
Website Url:
http://www.ymabs.com
Total Employee:
101+
Status:
Active
Contact:
1 212 847 9841
Email Addresses:
[email protected]
Total Funding:
338.8 M USD
Technology used in webpage:
Domain Not Resolving Apple Mobile Web Clips Icon LetsEncrypt Mobile Non Scaleable Content HSTS Cloudflare Hosting Pound Sterling Apache 2.4 COVID-19 Digital Ocean
Similar Organizations
Aimmune Therapeutics
Aimmune Therapeutics is a clinical-stage biopharmaceutical company that improves the lives of people with food allergies.
AVEO Oncology
AVEO is a biopharmaceutical company that offers drug development strategies for targeted cancer therapeutics.
Edgewise Therapeutics
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization.
Exuma Biotech
EXUMA Biotech is a clinical-stage biotechnology company that focuses on discovering and developing CAR-T cell products for solid tumors.
ReMission Foundation
An organization dedicated to supporting doctors and scientists researching innovative ways to treat and prevent various forms of cancer.
Semma Therapeutics
Semma Therapeutics was founded to develop transformative therapies for Type 1 diabetes patients.
Soligenix
Soligenix is a biopharmaceutical company that develops biodefense vaccines and therapeutics to treat rare diseases.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Sofinnova Investments
Sofinnova Investments investment in Private Equity Round - Y-mAbs Therapeutics
HBM Healthcare Investments
HBM Healthcare Investments investment in Private Equity Round - Y-mAbs Therapeutics
Scopia Capital
Scopia Capital investment in Private Equity Round - Y-mAbs Therapeutics
HBM Healthcare Investments
HBM Healthcare Investments investment in Private Equity Round - Y-mAbs Therapeutics
Key Employee Changes
Official Site Inspections
http://www.ymabs.com Semrush global rank: 3.31 M Semrush visits lastest month: 4.24 K
- Host name: 104.21.26.179
- IP address: 104.21.26.179
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Y-mAbs Therapeutics"
Management | Y-mAbs Therapeutics, Inc. - ir.ymabs.com
The Investor Relations website contains information about Y-mAbs Therapeutics, Inc.'s business for stockholders, potential investors, and financial analysts. See details»
Y-mAbs Therapeutics - Crunchbase Company Profile
YmAbs is a clinical stage biopharmaceutical company that discovers and develops innovative treatments for cancer patients. See details»
Y-mAbs Therapeutics (YMAB) Company Profile & Description
4 days ago Company profile for Y-mAbs Therapeutics, Inc. (YMAB) stock, with a description, list of executives, contact details and other key facts. See details»
Y-mAbs Therapeutics - 2025 Company Profile & Team - Tracxn
Jul 4, 2025 Y-mAbs Therapeutics - Provider of antibodies-based products targeting GD2 and B7H3 tumor antigens.. Public Company. Raised a total funding of $90M over 3 rounds from 5 investors. See details»
Y-mAbs Therapeutics - CAC2
Y-mAbs is a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer.nThe … See details»
Y-mAbs Therapeutics, Inc. - Drug pipelines, Patents, Clinical trials ...
May 7, 2025 Prior to the call and webcast, a slide presentation pertaining to the Company’s quarterly earnings will be made available on the Investor Relations section of the Y-mAbs … See details»
Y-mAbs - HBM Partners
YmAbs is a clinical stage biotechnology company specialized in developing novel antibody therapeutics to treat cancer. Several ongoing late-stage clinical trials significantly improve survival … See details»
For Investors | Y-mAbs Therapeutics, Inc.
DANYELZA is indicated, in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), for the treatment of pediatric patients 1 year of age and older and adult patients with … See details»
Board of Directors | Y-mAbs Therapeutics, Inc. - ir.ymabs.com
Previously, he served as the Chief Financial Officer of INC Research (now known as Syneos Health), a clinical research organization, from February 2011 to August 2013 after having served as a … See details»
Y-mAbs Therapeutics (YMAB) Stock Price & Overview
Jul 11, 2025 A detailed overview of Y-mAbs Therapeutics, Inc. (YMAB) stock, including real-time price, chart, key statistics, news, and more. See details»
Y-mAbs Announces Restructuring Plan and Provides Financial …
Jan 4, 2023 “We believe that this restructuring of the organization aligns our resources to efficiently leverage both the DANYELZA franchise and support development activities for our highly … See details»
Y-mAbs Announces Restructuring Plan and Provides Financial …
Jan 4, 2023 “We believe that this restructuring of the organization aligns our resources to efficiently leverage both the DANYELZA franchise and support development activities for our highly … See details»
Y-mAbs Therapeutics - Contacts, Employees, Board Members
YmAbs is a clinical stage biopharmaceutical company that discovers and develops innovative treatments for cancer patients. See details»
Y-mAbs Reports First Quarter 2025 Financial Results and Recent ...
May 13, 2025 Prior to the call and webcast, a slide presentation pertaining to the Company’s quarterly earnings will be made available on the Investor Relations section of the Y-mAbs … See details»
Y-mAbs Announces Publication of Phase 2 Interim Results in Nature ...
Mar 3, 2025 The article, titled “ The anti-GD2 monoclonal antibody naxitamab plus GM-CSF for relapsed or refractory high-risk neuroblastoma: a phase 2 clinical trial, ” details the results of a … See details»
Y-mAbs Therapeutics - Profiles & Contacts - Crunchbase
YmAbs is a clinical stage biopharmaceutical company that discovers and develops innovative treatments for cancer patients. See details»
Investor Overview | Y-mAbs Therapeutics, Inc.
May 13, 2025 The Investor Relations website contains information about Y-mAbs Therapeutics, Inc.'s business for stockholders, potential investors, and financial analysts. See details»
SEC Filing | Y-mAbs Therapeutics, Inc.
Jul 11, 2025 Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the … See details»
Y-mAbs Provides Strategic Business Update and 2025 Priorities
Dec 31, 2024 A live webcast will be available under the Events section of the Company’s investor relations website at ir.ymabs.com. The webcast will be archived and available for replay for 30 … See details»
Y-mAbs Reports First Quarter 2025 Financial Results and Recent ...
Mar 31, 2025 Reported Net Product Revenues of $20.9 million for the first quarter of 2025, a year-over-year increase of approximately 8% National Comprehensive Cancer Network ® (NCCN ® ) … See details»